Search Results - "Reiter, Robert Evan"

Pre-surgical 68 Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial by Djaileb, Loic, Armstrong, Wesley Robert, Thompson, Daniel, Gafita, Andrei, Farolfi, Andrea, Cooperberg, Matthew R., Carroll, Peter, Washington, Samuel L., Reiter, Robert Evan, Eiber, Matthias, Herrmann, Ken, Fendler, Wofgang P, Czernin, Johannes, Hope, Thomas A., Calais, Jeremie

“…285 Background: To compare the prognostic value of presurgical PSMA-PET and pelvic lymph nodes invasion (pN1) for biochemical recurrence (BCR) free-survival…”
Get full text

Association of aggressive prostate cancer features on whole-mount histopathology and quantitative measures on PSMA PET by Sonni, Ida, Kim, Daniel Hyeong Seok, Ter-Pogosyan, Arthur, Grogan, Tristan, Barroso, Nashla, Ahuja, Preeti, Soin, Priti, Calais, Jeremie, Reiter, Robert Evan, Hsu, William, Czernin, Johannes, Sisk, Anthony E, Raman, Steven

“…289 Background: The intraductal carcinoma (IDC) and the large cribriform growth pattern (LCP) are two architectural patterns of prostate cancer (PC) associated…”
Get full text

PSMA PET/CT and mpMRI discrepancies in prostate cancer detection with whole-mount histopathology gold standard by Sonni, Ida, Doddipalli, Sahith, Deol, Madhvi, Ban, David, Kim, Hye Ok, Grogan, Tristan, Ahuja, Preeti, Barroso, Nashla, Zong, Yang, Soin, Priti, Weiner, Adam B, Sisk, Anthony E, Calais, Jeremie, Hsu, William, Reiter, Robert Evan, Czernin, Johannes, Raman, Steven

“…284 Background: Multiparametric MRI (mpMRI) and PSMA-PET are complementary imaging modalities used in the pre-surgical evaluation of patients with prostate…”
Get full text

Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial by Nikitas, John, Rettig, Matthew, Shen, John, Reiter, Robert Evan, Lee, Alan, Steinberg, Michael L., Valle, Luca Faustino, Sachdeva, Ankush, Romero, Tahmineh, Calais, Jeremie, Czernin, Johannes, Nickols, Nicholas George, Kishan, Amar Upadhyaya

“…174 Background: Nearly all men with metastatic hormone-sensitive prostate cancer who receive intermittent androgen deprivation therapy (ADT) will experience a…”
Get full text

PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis by Armstrong, Wesley Robert, Clark, Kevyn J, Smith, Clayton P, Thin, Pan, Djaileb, Loic, Benz, Matthias R., Reiter, Robert Evan, Rettig, Matthew, Czernin, Johannes, Nickols, Nicholas George, Kishan, Amar Upadhyaya, Calais, Jeremie

“…5091 Background: The EMBARK trial is a phase 3, randomized, study evaluating use of enzalutamide with or without concomitant leuprolide in non-metastatic…”
Get full text

PSMA PET guided salvage radiotherapy among patients with prostate cancer in the post-prostatectomy setting: A single center post-hoc analysis by Smith, Clayton P, Armstrong, Wesley Robert, Clark, Kevyn J, Moore, Jonathan, Roberts, Makayla, Farolfi, Andrea, Reiter, Robert Evan, Rettig, Matthew, Shen, John, Valle, Luca, Nickols, Nicholas George, Steinberg, Michael L., Czernin, Johannes, Kishan, Amar Upadhyaya, Calais, Jeremie

“…5009 Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) shows improved sensitivity and specificity for detection of…”
Get full text

Pre-surgical 68 Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial by Djaileb, Loic, Armstrong, Wesley Robert, Thompson, Daniel, Gafita, Andrei, Farolfi, Andrea, Grogan, Tristan, Cooperberg, Matthew R., Carroll, Peter, Washington, Samuel L., Reiter, Robert Evan, Eiber, Matthias, Herrmann, Ken, Fendler, Wolfgang P., Czernin, Johannes, Hope, Thomas A., Calais, Jeremie

“…5090 Background: To compare the prognostic value of presurgical PSMA-PET and pelvic lymph nodes invasion (pN1) for biochemical recurrence (BCR) free-survival…”
Get full text

Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer by Nickols, Nicholas George, Tsai, Sonny, Kane, Nathanael, Diaz-Perez, Silvia, Ghayouri, Leila, Tran, Samantha, Duriseti, Sai, Valle, Luca, Lee, Steve Pai-hsun, Kwon, Robert, Gin, Greg E, Chang, Michael George, Chao, Hann-Hsiang, Steinberg, Michael L., Reiter, Robert Evan, Kishan, Amar Upadhyaya, Berenji, Gholam Reza, Aronson, William, Garraway, Isla, Rettig, Matthew

“…163 Background: Treatment paradigms for oligometastatic castration-sensitive prostate cancer patients are evolving. Molecular imaging improves staging,…”
Get full text

Stereotactic intensity modulated radiotherapy after radical prostatectomy (SCIMITAR): Two-year quality of life and toxicity outcomes of a multicenter phase II trial by Nikitas, John, Ballas, Leslie K., Franco, Antonio, Lynch, Connor, Ma, Ting Martin, Valle, Luca Faustino, Romero, Tahmineh, Sachdeva, Ankush, Chong, Natalie, Basehart, Vincent, Reiter, Robert Evan, Saigal, Christopher, Chamie, Karim, Litwin, Mark S., Rettig, Matthew, Nickols, Nicholas George, Steinberg, Michael L., Cao, Minsong, Liauw, Stanley L., Kishan, Amar Upadhyaya

“…317 Background: Postoperative radiotherapy for men with biochemical recurrence or adverse pathologic features after radical prostatectomy (RP) remains…”
Get full text

Predictive value of extra-prostatic disease detection by pre-operative PSMA-PET for biochemical recurrence-free survival in patients treated with radical prostatectomy: Follow-up analysis of a multicenter prospective phase 3 imaging trial by Djaileb, Loic, Armstrong, Wesley R, Thompson, Daniel, Nguyen, Kathleen, Gafita, Andrei, Farolfi, Andrea, Rajagopal, Abhejit, Juarez, Roxanna, Cooperberg, Matthew R., Carroll, Peter, Washington, Samuel L., Czernin, Johannes, Reiter, Robert Evan, Hope, Thomas A., Calais, Jeremie

“…5088 Background: To assess the predictive value of pre-operative PSMA-PET staging for biochemical recurrence (BCR) free-survival (BCR-FS) in patients treated…”
Get full text

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies by Weiner, Adam B, Liu, Yang, Hakansson, Alexander K., Zhao, Xin, Proudfoot, James Alexander, Zhang, JJ Haijing, Karnes, R. Jeffrey, Den, Robert Benjamin, Kishan, Amar Upadhyaya, Reiter, Robert Evan, Hamid, Anis, Ross, Ashley, Tran, Phuoc T., Chua, Melvin L.K. Lee Kiang, Spratt, Daniel Eidelberg, Attard, Gerhardt, Lotan, Tamara L., Sweeney, Christopher J, Davicioni, Elai, Schaeffer, Edward M.

“…241 Background: We previously reported on the use of gene expression profiling to characterize four primary subtypes in an analysis of over 100,000 prostate…”
Get full text

Radiographic-pathologic concordance in the workup of locally radiorecurrent prostate cancer by Valle, Luca Faustino, Calais, Jeremie, Marks, Leonard S., Raman, Steven, Reiter, Robert Evan, Rettig, Matthew, Shen, John, Czernin, Johannes, Weiner, Adam B, Steinberg, Michael L., Nickols, Nicholas George, Chang, Albert J, Boutros, Paul Christopher, Ye, Huihui, Hotta, Masatoshi, Huang, Rong Rong, Kishan, Amar Upadhyaya

“…313 Background: Advanced molecular PET/CT (mPET) studies are increasingly being utilized in conjunction with multiparametric MRI (mpMRI) to evaluate the burden…”
Get full text

Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings by Sonni, Ida, Eiber, Matthias, Fendler, Wolfgang, Alano, Rejah M., Vangala, Sitaram S., Kishan, Amar Upadhyaya, Nickols, Nicholas George, Rettig, Matthew, Reiter, Robert Evan, Czernin, Johannes, Calais, Jeremie

“…Abstract only 26 Background: The goal of this study was to determine the impact of 68 Ga-PSMA-11 PET/CT on initial and subsequent management decisions in a…”
Get full text

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard by Sonni, Ida, Felker, Ely, Lenis, Andrew Thomas, Sisk, Anthony E, Bahri, Shadfar, Auerbach, Martin S., Armstrong, Wesley R, Suvannarerg, Voraparee, Tubtawee, Teeravut, Grogan, Tristan, Elashoff, David, Czernin, Johannes, Raman, Steven, Reiter, Robert Evan, Calais, Jeremie

“…Abstract only 193 Background: The local staging of prostate cancer relies on systematic or targeted biopsies and multiparametric magnetic resonance imaging…”
Get full text

Transcriptional profiling of matched biopsies reveals molecular determinants of enzalutamide resistance by Westbrook, Thomas, Guan, Xiangnan, Udager, Aaron M., Haffner, Michael, Beer, Tomasz M., Aggarwal, Rahul Raj, Ryan, Charles J., Gleave, Martin, Huang, Jiaoti, Evans, Christopher P., Reiter, Robert Evan, Witte, Owen, Rettig, Matthew, Stuart, Josh, Thomas, George V., Feng, Felix Y, Small, Eric Jay, Yates, Joel, Xia, Zheng, Alumkal, Joshi J.

“…5058 Background: Castration-resistant prostate cancer (CRPC) is the lethal form of the disease. One of the principal therapies in CRPC is the potent androgen…”
Get full text

Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) by de Kouchkovsky, Ivan, Zhang, Li, Huang, Jiaoti, Trepka, Kai, Chou, Jonathan, Foye, Adam, Shui, David, Wong, Chris, Friedl, Verena, Weinstein, Alana, Hope, Thomas A, Quigley, David A., Stuart, Josh, Beer, Tomasz M., Reiter, Robert Evan, Gleave, Martin E., Evans, Christopher P, Feng, Felix Y, Small, Eric Jay, Aggarwal, Rahul Raj

“…Abstract only 167 Background: Low PSMA uptake on positron-emission tomography is seen in up to 30% of mCRPC pts and represents a clinically distinct subgroup…”
Get full text

Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy by Calais, Jeremie, Ceci, Francesco, Nguyen, Kathleen, Gartmann, Jeannine, Eiber, Matthias, Reiter, Robert Evan, Kishan, Amar Upadhyaya, Jadvar, Hossein, Fendler, Wolfgang P, Czernin, Johannes

“…Abstract only 15 Background: 18F-Fluciclovine PET/CT (FACBC) is standard-of-care in US for localization of prostate cancer (PCa) biochemical recurrence (BCR)…”
Get full text

Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer by Parikh, Neil Rohit, Chang, Eric M., Nickols, Nicholas George, Rettig, Matthew, Raldow, Ann C., Steinberg, Michael L., Koontz, Bridget F., Vapiwala, Neha, Deville, Curtiland, Feng, Felix Y, Spratt, Daniel Eidelberg, Reiter, Robert Evan, Phillips, Ryan, Tran, Phuoc T., Kishan, Amar Upadhyaya

“…Abstract only 211 Background: Low-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC) has historically been treated with lifelong androgen…”
Get full text

Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial by Fendler, Wolfgang, Ferdinandus, Justin, Calais, Jeremie, Eiber, Matthias, Flavell, Robert R., Mishoe, Ashley, Feng, Felix Y, Nguyen, Hao Gia, Reiter, Robert Evan, Rettig, Matthew, Gartmann, Jeannine, Smith, Raven, Small, Eric Jay, Slavik, Roger, Carroll, Peter, Herrmann, Ken, Czernin, Johannes, Hope, Thomas

“…Abstract only 292 Background: Prostate-specific membrane antigen ligand positron emission tomography (PSMA PET) induced management changes in up to every…”
Get full text

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer by Guan, Xiangnan, Sun, Duanchen, Lu, Eric, Urrutia, Joshua A, Reiter, Robert Evan, Rettig, Matthew, Evans, Christopher P, Lara, Jr, Primo, Gleave, Martin, Beer, Tomasz M, Thomas, George V, Huang, Jiaoti, Aggarwal, Rahul R, Quigley, David A, Foye, Adam, Chen, William S, Youngren, Jack, Weinstein, Alana S, Stuart, Joshua M, Feng, Felix Y, Small, Eric J, Xia, Zheng, Alumkal, Joshi J

“…The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses of whole-genome sequencing and RNA sequencing…”
Get full text